



DAFTAR PUSTAKA



DAFTAR PUSTAKA

- Ahadi, G.D. and Zain, N.N.L.E. (2023) 'Pemeriksaan Uji Kenormalan dengan Kolmogorov-Smirnov, Anderson-Darling dan Shapiro-Wilk', *EIGEN MATHEMATICS JOURNAL*, pp. 11–19. Available at: <https://doi.org/10.29303/emj.v6i1.131>.
- Ahmed, M.H., Ghatge, M.S. and Safo, M.K. (2020) 'Hemoglobin: Structure, Function and Allostery', *Subcellular Biochemistry*. Springer, pp. 345–382. Available at: https://doi.org/10.1007/978-3-030-41769-7_14.
- Anisah, A., Sumekar, D.W. and Budiarti, E. (2021) 'Hubungan Demografi dan Komorbid dengan Kejadian Tuberkulosis Resisten Obat (TB RO)', *Jurnal Ilmiah Kesehatan Sandi Husada*, 10(2), pp. 568–574. Available at: <https://doi.org/10.35816/jiskh.v10i2.655>.
- Apgar, S. and Suryani (2025) 'Comparing The Hematological Effects of BPaL/BPaLM Regimens to Those of Standard Regimens in the Treatment of Drug-Resistant Tuberculosis: A Narrative Review', *Pharmacon: Jurnal Farmasi Indonesia*, pp. 280–285. Available at: <https://doi.org/10.23917/pharmacon.v22i2.12071>.
- Badan Pusat Statistik Kabupaten Gresik (2023) *Jumlah Kasus Tuberculosis_TB 2023*. Available at: <https://gresikkab.bps.go.id/id/statistics-table/2/Mjc0lzl=/number-of-cases-of-tuberculosis.html> (Accessed: 30 January 2025).
- Bawonte, T.G., Mambo, C.D. and Masengi, A.S.R. (2021) 'Faktor-Faktor Yang Mempengaruhi Tuberculosis Multidrug Resistance (TB MDR)', 9(1), pp. 117–125. Available at: <https://doi.org/10.35790/ebm.9.1.2021.31949>.
- Bedaso, M.H. and Kalil, F.S. (2021) 'Trends of drug resistance tuberculosis from 2014 to 2018, bale zone, oromia region, Ethiopia', *Infection and Drug Resistance*, 14, pp. 2073–2078. Available at: <https://doi.org/10.2147/IDR.S300723>.
- Centers for Disease Control and Prevention (2019) *Self-Study Modules On Tuberculosis Transmission and Pathogenesis of Tuberculosis*. Atlanta. Available at: https://www.cdc.gov/tb/media/pdfs/Self_Study_Module_1_Transmission_and_Pathogenesis_of_Tuberculosis.pdf (Accessed: 11 March 2025).
- Chaparro, C.M. and Suchdev, P.S. (2019) 'Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries', *Annals of the New York Academy of Sciences*. Blackwell Publishing Inc., pp. 15–31. Available at: <https://doi.org/10.1111/nyas.14092>.
- Chauhan, A. and Pundir, R. (2023) 'ETHIONAMIDE : AN EXPLORATORY REVIEW', *International Journal of Research and Analytical Reviews* [Preprint]. Available at: www.ijrar.org.

- Conradie, F. *et al.* (2020) 'Treatment of Highly Drug-Resistant Pulmonary Tuberculosis', *New England Journal of Medicine*, 382(10), pp. 893–902. Available at: <https://doi.org/10.1056/nejmoa1901814>.
- Conradie, F. *et al.* (2022a) 'Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis', *New England Journal of Medicine*, 387(9), pp. 810–823. Available at: <https://doi.org/10.1056/nejmoa2119430>.
- Dasaradhan, T. *et al.* (2022) 'Tuberculosis-Associated Anemia: A Narrative Review', *Cureus* [Preprint]. Available at: <https://doi.org/10.7759/cureus.27746>.
- Deshpande, D. *et al.* (2018) 'Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis', *Clinical Infectious Diseases*, 67(suppl_3), pp. S317–S326. Available at: <https://doi.org/10.1093/cid/ciy609>.
- Destri, C. *et al.* (2024) 'Analysis of Complete Blood Count (Cbc) and Erythrocyte Sedimentation Rate (Esr) Results in Multidrug Resistant Tuberculosis (Mdr-Tb) Patients', *Eduvest-Journal of Universal Studies*, 4(5), pp. 4079–4090. Available at: <http://eduvest.greenvest.co.id>.
- Van Deun, A. *et al.* (2020) 'World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward', *International Journal of Antimicrobial Agents*. Elsevier B.V. Available at: <https://doi.org/10.1016/j.ijantimicag.2019.10.003>.
- Dheda, K. *et al.* (2017) 'The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis', *The Lancet Respiratory Medicine*. Lancet Publishing Group, pp. 291–360. Available at: [https://doi.org/10.1016/S2213-2600\(17\)30079-6](https://doi.org/10.1016/S2213-2600(17)30079-6).
- Ditse, Z., Lamers, M.H. and Warner, D.F. (2017) 'DNA Replication in Mycobacterium tuberculosis', *Microbiology Spectrum*, 5(2). Available at: <https://doi.org/10.1128/microbiolspec.tbtb2-0027-2016>.
- Hasan, T. *et al.* (2024) 'The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis', *Clinical Infectious Diseases*, 78(3), pp. 730–741. Available at: <https://doi.org/10.1093/cid/ciad653>.
- Hashemian, S.M.R., Farhadi, T. and Ganjparvar, M. (2018) 'Linezolid: A review of its properties, function, and use in critical care', *Drug Design, Development and Therapy*. Dove Medical Press Ltd., pp. 1759–1767. Available at: <https://doi.org/10.2147/DDDT.S164515>.
- Ismail, A. and Srouji, N. Al (2020) 'Anemia of Chronic Disease: Epidemiology and Pathophysiological Mechanisms – Literature Review', *Global Journal of Medical Therapeutics*, 2(4). Available at: <https://doi.org/10.46982/gjmt.2020.109>.

- Kassa, E. *et al.* (2016) 'Effect of anti-tuberculosis drugs on hematological profiles of tuberculosis patients attending at University of Gondar Hospital, Northwest Ethiopia', *BMC Hematology*, 16(1). Available at: <https://doi.org/10.1186/s12878-015-0037-1>.
- Katzung, B.G.. (2018) *Basic & clinical pharmacology*. 14th ed. New York: McGraw-Hill.
- Kementerian Kesehatan Republik Indonesia (2019) *Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/755/2019 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis*. Jakarta.
- Kementerian Kesehatan Republik Indonesia (2020) *Peraturan Pemerintah Republik Indonesia Nomor 21 Tahun 2020 Tentang Pembatasan Sosial Berskala Besar Dalam Rangka Percepatan Penanganan Corona Wrus Disease 2019 (Covid-19)*. Jakarta.
- Kementerian Kesehatan Republik Indonesia (2020b) *Petunjuk Teknis Penatalaksanaan Tuberkulosis Resisten Obat Di Indonesia*. Jakarta.
- Kementerian Kesehatan Republik Indonesia (2023) *Deteksi TBC Capai Rekor Tertinggi di Tahun 2022, Kementerian Kesehatan Republik Indonesia*. Available at: <https://kemkes.go.id/id/deteksi-tbc-capai-rekor-tertinggi-ditahun-2022> (Accessed: 29 January 2025).
- Kementerian Kesehatan Republik Indonesia (2024) *Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia*. Jakarta: Kemenkes.
- Khawbung, J.L., Nath, D. and Chakraborty, S. (2021) 'Drug resistant Tuberculosis: A review', *Comparative Immunology, Microbiology and Infectious Diseases*. Elsevier Ltd. Available at: <https://doi.org/10.1016/j.cimid.2020.101574>.
- Koch, A., Cox, H. and Mizrahi, V. (2018) 'Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment', *Current Opinion in Pharmacology*. Elsevier Ltd, pp. 7–15. Available at: <https://doi.org/10.1016/j.coph.2018.05.013>.
- Lamont, E.A., Dillon, N.A. and Baughn, A.D. (2020) 'The Bewildering Antitubercular Action of Pyrazinamide'. Available at: <https://doi.org/10.1128/MMBR>.
- Lange, C. *et al.* (2018) 'Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment', *Respirology*, 23(7), pp. 656–673. Available at: <https://doi.org/10.1111/resp.13304>.
- Liebenberg, D., Gordhan, B.G. and Kana, B.D. (2022) 'Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management', *Frontiers in Cellular and Infection Microbiology*. Frontiers Media S.A. Available at: <https://doi.org/10.3389/fcimb.2022.943545>.
- Ma, H. *et al.* (2026) 'Antibiotic Mechanisms and Resistance: Molecular Insights and Therapeutic Strategies', *Antibiotics*. Multidisciplinary Digital Publishing Institute (MDPI). Available at: <https://doi.org/10.3390/antibiotics15040351>.

- Mariana, N. *et al.* (2025) ‘Adverse drug reactions to the nine-month all-oral and 18-month regimens for multidrug-resistant tuberculosis in Indonesia’, *International Journal of Risk & Safety in Medicine* [Preprint]. Available at: <https://doi.org/10.1177/09246479251370581>.
- Ma’rifah, S., Pangesti, I. and Faizal, I.A. (2023) ‘Pengaruh Pengobatan Multi Drug Resistant Tuberculosis (TBMDR) Terhadap Kadar Hemoglobin Dan Hematokrit Di Rsud Cilacap Pada Januari 2020 Sampai Desember 2022’. Available at: <http://ejournal.universitalirsyad.ac.id/index.php/JP/article/download/323/215> (Accessed: 21 January 2026).
- Mary Rose S, L. and Cyruz P, Dr.Tu. (2025) ‘Perceptions, Predictors, and Pathways: A Mixed Methods Study on TPT Adherence among Household Contacts of TB Cases’, p. 1876. Available at: <https://doi.org/10.51244/IJRSI>.
- Mase, S. *et al.* (2020) ‘Bedaquiline for the treatment of multidrug-resistant tuberculosis in the United States’, *Clinical Infectious Diseases*, 71(4), pp. 1010–1016. Available at: <https://doi.org/10.1093/cid/ciz914>.
- Maulida, D. *et al.* (2024) ‘Prevalensi dan Karakteristik Pasien Tuberkulosis Paru Resisten Obat (TB-RO) dengan Diabetes Melitus Tipe 2 di Klinik TB-RO Rumah Sakit Umum Pusat Dr. Hasan Sadikin, Bandung Prevalensi dan Karakteristik Pasien Tuberkulosis Paru Resisten Obat (TB-RO) dengan Diabetes Melitus Tipe 2 di Klinik TB-RO Rumah Sakit Umum Pusat Dr. Hasan Sadikin, Bandung’, *Jurnal Penyakit Dalam Indonesia*, 11(1). Available at: <https://doi.org/10.7454/jpdi.v11i2.1550>.
- McDonough, J.E. *et al.* (2015) *Fishman’s Pulmonary Diseases and Disorders*. Fifth Edition. Edited by M.A. Grippi *et al.* McGraw-Hill Education.
- Minardi, M.L. *et al.* (2021) ‘Common and rare hematological manifestations and adverse drug events during treatment of active tb: A state of art’, *Microorganisms*, 9(7). Available at: <https://doi.org/10.3390/microorganisms9071477>.
- Nguyen, T.N.A. *et al.* (2019) ‘Molecular diagnosis of drug-resistant tuberculosis: A literature review’, *Frontiers in Microbiology*, 10(MAR). Available at: <https://doi.org/10.3389/fmicb.2019.00794>.
- Occhineri, S. *et al.* (2022) ‘Pretomanid for tuberculosis treatment: an update for clinical purposes’, *Current Research in Pharmacology and Drug Discovery*, 3, p. 100128. Available at: <https://doi.org/10.1016/j.crphar.2022.100128>.
- OECD/WHO (2024) *Health at a Glance: Asia/Pacific 2024*. Paris: OECD. Available at: <https://doi.org/10.1787/51fed7e9-en>.
- Oehadian, A. *et al.* (2022a) ‘Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria’, *Tuberculosis and Respiratory Diseases*. Korean National Tuberculosis Association, pp. 111–121. Available at: <https://doi.org/10.4046/TRD.2021.0122>.

- Pai, H. *et al.* (2022) 'Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis', *BMC Infectious Diseases*, 22(1). Available at: <https://doi.org/10.1186/s12879-022-07861-x>.
- Paramothayan, S. (2019) *Essential Respiratory Medicine*. 1st ed. 111 River Street, Hoboken: Wiley Balckwell.
- Pradipta, I.S. *et al.* (2018) 'Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis', *Journal of Infection*. W.B. Saunders Ltd, pp. 469–478. Available at: <https://doi.org/10.1016/j.jinf.2018.10.004>.
- Prasad, R., Singh, A. and Gupta, N. (2021) 'Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis', *Annals of the National Academy of Medical Sciences (India)*, 57, pp. 16–35. Available at: <https://doi.org/10.1055/s-0040-1722535>.
- Pratama, N.Y.I. (2020) 'Analisis Efek Samping Hematologi Linezolid Pada Pasien TB RO Dengan Terapi Individual (Penelitian dilaksanakan di Poli Rawat Jalan TB MDR RSUD Dr. Soetomo Surabaya)'.
- Reinhart, W.H. (2016) 'The optimum hematocrit', *Clinical Hemorheology and Microcirculation*, 64(4), pp. 575–585. Available at: <https://doi.org/10.3233/CH-168032>.
- Ristian Octavia, D. *et al.* (2024) 'Algoritme Naranjo sebagai Metode Identifikasi Dini Efek Samping Obat pada Pasien Tuberkulosis Resisten Obat di RS Muhammadiyah Lamongan', *Jurnal Ilmu Kefarmasian*, 5(2).
- Roger, C., Roberts, J.A. and Muller, L. (2018) 'Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones', *Clinical Pharmacokinetics*. Springer International Publishing, pp. 559–575. Available at: <https://doi.org/10.1007/s40262-017-0601-x>.
- RSUD Ibnu Sina Kabupaten Gresik (2024) *Batas Petir: Obati Sampai Tuntas Penderita TB-MDR*. Available at: <https://rsudibnusina.gresikkab.go.id/web/bataspetir> (Accessed: 30 January 2025).
- Sarathy, J.P., Gruber, G. and Dick, T. (2019) 'Re-understanding the mechanisms of action of the anti-mycobacterial drug bedaquiline', *Antibiotics*. MDPI AG. Available at: <https://doi.org/10.3390/antibiotics8040261>.
- Sherwood, Lauralee. and Ward, Christopher. (2019) *Human physiology : from cells to systems*. 4th ed. Nelson.
- Silva, D.R. *et al.* (2018) 'Risk factors for tuberculosis: Diabetes, smoking, alcohol use, and the use of other drugs', *Jornal Brasileiro de Pneumologia*. Sociedade Brasileira de Pneumologia e Tisiologia, pp. 145–152. Available at: <https://doi.org/10.1590/s1806-37562017000000443>.
- Subhaktiyasa, P.G. (2024) 'Menentukan Populasi dan Sampel: Pendekatan Metodologi Penelitian Kuantitatif dan Kualitatif', *Jurnal Ilmiah Profesi*

- Pendidikan*, 9(4), pp. 2721–2731. Available at: <https://doi.org/10.29303/jipp.v9i4.2657>.
- Sutrisna, M. and Elsi Rahmadani (2022) ‘Hubungan Usia dan Jenis Kelamin dengan TB MDR’, *Sehat Rakyat: Jurnal Kesehatan Masyarakat*, 1(4), pp. 370–376. Available at: <https://doi.org/10.54259/sehatrakyat.v1i4.1168>.
- Thomas, L. *et al.* (2022) ‘Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models’, *European Journal of Clinical Pharmacology*. Springer Science and Business Media Deutschland GmbH, pp. 1535–1553. Available at: <https://doi.org/10.1007/s00228-022-03362-7>.
- Thuy, H.T.T. *et al.* (2025) ‘Efficacy and safety data on pretomanid for drug-resistant TB’, *IJTLD OPEN*, 2(2), pp. 73–82. Available at: <https://doi.org/10.5588/ijtldopen.24.0360>.
- Wahdah, R., Setyowati, H. and Salafas, E. (2019) *Hubungan Pola Makan Dengan Kejadian Anemia Di Pondok Pesantren Al Mas’udiyah Puteri 2 Bleter Kabupaten Semarang Tahun 2019, Eti Salafas) Journal of Holistics and Health Sciences*.
- Weiss, G., Ganz, T. and Goodnough, L.T. (2019) *Review Series IRON METABOLISM AND ITS DISORDERS Anemia of inflammation*. Available at: <http://ashpublications.org/blood/article-pdf/133/1/40/1551537/blood856500.pdf>.
- Wiciński, M. *et al.* (2020) ‘Anemia of chronic diseases: Wider diagnostics—better treatment?’, *Nutrients*, 12(6), pp. 1–17. Available at: <https://doi.org/10.3390/nu12061784>.
- World Health Organization (2019) *WHO consolidated guidelines on drug-resistant tuberculosis treatment*. Geneva: World Health Organization.
- World Health Organization (2022) *Global tuberculosis report 2022: Drug-resistant TB*, World Health Organization. Available at: <https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2022/tb-disease-burden/2-3-drug-resistant-tb> (Accessed: 30 January 2025).
- World Health Organization (2024a) *2024 Global tuberculosis report*. Geneva.
- World Health Organization (2024b) *Guideline on haemoglobin cutoffs to define anaemia in individuals and populations*. Geneva: World Health Organization.
- Yavorkovsky, L.L. (2021) ‘Mean corpuscular volume, hematocrit and polycythemia’, *Hematology (United Kingdom)*, 26(1), pp. 881–884. Available at: <https://doi.org/10.1080/16078454.2021.1994173>.
- Zalfa, H., Kulsum, I. and Suryadinata, H. (2024) ‘Gambaran Klinis Pasien Terduga Tuberkulosis Paru Resisten Obat (TB-RO) dengan Kolonisasi Candida sp. di Rumah Sakit Hasan Sadikin Bandung’, *Jurnal Penyakit Dalam Indonesia*, 11(1). Available at: <https://doi.org/10.7454/jpdi.v11i1.1499>.